Kowal Investment Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Kowal Investment Group’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2	Closed	–	–	911
2021 Q3	$0	Buy	+2	New	+$35	﹤0.01%	1021

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kowal Investment Group's VNDA Position: Q4 2021 in Review

Kowal Investment Group sold out of Vanda Pharmaceuticals (VNDA) in Q4 2021, closing a stake of 2 shares.

Kowal Investment Group first reported a position in VNDA in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 198 funds tracked by Wall St. Rank hold VNDA as of Q4 2021.

Kowal Investment Group reported no remaining Vanda Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Kowal Investment Group sold 2 Vanda Pharmaceuticals shares in Q4 2021.
Kowal Investment Group first reported a position in Vanda Pharmaceuticals in Q3 2021 and held it in 1 quarter.
Kowal Investment Group's Vanda Pharmaceuticals position peaked at $0 in Q3 2021.
198 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2021.

Based on Kowal Investment Group's 13F filing for Q4 2021, filed 11 Feb 2022.